CL2009001637A1 - N-(5-(4-((6-cianopiridin-3-il)metoxi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciclopropancarboxamida, inhibidor de jak, composicion farmaceutica; y su uso en el tratamiento y prevencion de enfermedades proliferativas e inflamatorias, tales como osteoartritis, enfermedad de crohn, artritis reumatoide, psoriasis, entre otras. - Google Patents

N-(5-(4-((6-cianopiridin-3-il)metoxi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciclopropancarboxamida, inhibidor de jak, composicion farmaceutica; y su uso en el tratamiento y prevencion de enfermedades proliferativas e inflamatorias, tales como osteoartritis, enfermedad de crohn, artritis reumatoide, psoriasis, entre otras.

Info

Publication number
CL2009001637A1
CL2009001637A1 CL2009001637A CL2009001637A CL2009001637A1 CL 2009001637 A1 CL2009001637 A1 CL 2009001637A1 CL 2009001637 A CL2009001637 A CL 2009001637A CL 2009001637 A CL2009001637 A CL 2009001637A CL 2009001637 A1 CL2009001637 A1 CL 2009001637A1
Authority
CL
Chile
Prior art keywords
disease
osteoarthritis
prevention
pharmaceutical composition
diseases
Prior art date
Application number
CL2009001637A
Other languages
English (en)
Inventor
Christel Jeanne Marie Menet
Javier Blanc
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CL2009001637A1 publication Critical patent/CL2009001637A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO QUE COMPRENDE LA FORMULA VIA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.<br /> UNA COMPOSICION  FARMACEUTICA QUE COMPRENDE UN PORTADOR  FARMACEUTICAMENTE ACEPTABLE Y UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA DE DICHO COMPUESTO.<br /> USO DE DICHO COMPUESTO PARA EL TRATAMIENTO, PREVENCION O PRIFOLAXIS DE ENFERMEDADES QUE INVOLUCRAN LA DEGRADACION DEL CARTILAGO, LA DEGRADACION DE LAS ARTICULACIONES Y/O HUESO TALES COMO OSTEOARTRITIS Y/O AFECCIONES QUE INVOLUCRAN LA INFLAMACION O RESPUESTAS INMUNES, TALES COMO LA ENFERMEDAD DE CROHN, ARTRITIS REUMANOIDE , PSORIASIS, ENFERMEDAD ALERGICA DE LAS VIAS  RESPIRATORIAS  ( TALES COMO ASMA, RINITIS), ARTRITIS IDIOPATICA JUVENIL, COLITIS, ENFERMEDAD INFLAMATORIA INTESTINAL, ESTADOS  DE ENFERMEDAD CONDUCIDOS  POR ENDOTOXINA (TALES COMO COMPLICACIONES LUEGO DE CIRUGIA DE BYPASS O ESTADOS DE ENDOTOXINA CRONICOS  QUE CONTRIBUYEN A POR EJEMPLO INSUFICIENCIA  CARDIACA CRONICA ), ENFERMEDADES QUE INVOLUCRAN EL DETERIORO DEL RECAMBIO DEL CARTILAGO (TALES COMO ENFERMEDADES QUE  INVOLUCRAN LA ESTIMULACION  ANABOLICA DE LOS CONDROCITOS), MALFORMACIONES CONGENITAS DEL CARTILAGO, ENFERMEDADES ASOCIADAS CON LA HIPERSECRECION DE IL6 Y EL RECHAZO DE TRASPLANTES ( TALES COMO RECHAZO DEL TRASPLANTES DE ORGANOS).<br /> USO DE DICHO COMPUESTO PARA EL TRATAMIENTO DE LAS ENFERMEDADES PROLIFERATIVAS.<br />  
CL2009001637A 2008-07-25 2009-07-23 N-(5-(4-((6-cianopiridin-3-il)metoxi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciclopropancarboxamida, inhibidor de jak, composicion farmaceutica; y su uso en el tratamiento y prevencion de enfermedades proliferativas e inflamatorias, tales como osteoartritis, enfermedad de crohn, artritis reumatoide, psoriasis, entre otras. CL2009001637A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13592008P 2008-07-25 2008-07-25
US22068509P 2009-06-26 2009-06-26

Publications (1)

Publication Number Publication Date
CL2009001637A1 true CL2009001637A1 (es) 2010-02-19

Family

ID=41021059

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001637A CL2009001637A1 (es) 2008-07-25 2009-07-23 N-(5-(4-((6-cianopiridin-3-il)metoxi)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il)ciclopropancarboxamida, inhibidor de jak, composicion farmaceutica; y su uso en el tratamiento y prevencion de enfermedades proliferativas e inflamatorias, tales como osteoartritis, enfermedad de crohn, artritis reumatoide, psoriasis, entre otras.

Country Status (35)

Country Link
US (5) US8853240B2 (es)
EP (2) EP2361251B1 (es)
JP (2) JP5559168B2 (es)
KR (2) KR101711911B1 (es)
CN (2) CN102105471B (es)
AR (1) AR072875A1 (es)
AU (2) AU2009273143B2 (es)
BR (2) BRPI0916862B8 (es)
CA (2) CA2730757A1 (es)
CL (1) CL2009001637A1 (es)
CO (1) CO6361925A2 (es)
CR (1) CR20110092A (es)
CY (2) CY1113945T1 (es)
DK (2) DK2361251T3 (es)
DO (1) DOP2011000022A (es)
EA (2) EA018587B1 (es)
ES (2) ES2406691T3 (es)
HR (2) HRP20140681T1 (es)
IL (2) IL210262A (es)
JO (1) JO3041B1 (es)
MA (1) MA32551B1 (es)
ME (1) ME02046B (es)
MX (2) MX2011000756A (es)
MY (1) MY157615A (es)
NZ (1) NZ590646A (es)
PE (1) PE20100152A1 (es)
PL (2) PL2346864T3 (es)
PT (2) PT2361251E (es)
RS (2) RS53406B (es)
SI (2) SI2361251T1 (es)
SM (2) SMT201300051B (es)
TW (1) TWI447118B (es)
UY (1) UY32006A (es)
WO (2) WO2010010191A1 (es)
ZA (2) ZA201100396B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
US20100331222A1 (en) * 2009-06-26 2010-12-30 Basf Se Process for producing cellulose beads from solutions of cellulose in ionic liquid
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2566333A4 (en) * 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
CN103965114B (zh) * 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
CN105339370B (zh) * 2013-06-19 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎症性疾病的化合物和及其药物组合物
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
CA2934251C (en) 2013-12-20 2024-01-02 3-V Biosciences, Inc. A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
WO2016119700A1 (en) 2015-01-28 2016-08-04 Jn Therapeutics Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
KR20170134750A (ko) * 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
EP3290418B1 (en) * 2015-04-29 2019-05-15 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase (jak) inhibitors
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012771A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Crystalline filgotinib sulfonic acid addition salts
WO2017012773A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Solid forms of filgotinib free base
WO2017012770A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Acid addition salts of filgotinib
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN108349974B (zh) * 2016-02-02 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
EP3492468B1 (en) * 2016-07-26 2022-02-23 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
TWI752098B (zh) * 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6953527B2 (ja) * 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ．ベー． 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
SG11201902882UA (en) * 2016-10-26 2019-05-30 Janssen Pharmaceutica Nv Fused azaheterocyclic compounds and their use as ampa receptor modulators
EA039344B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
CN108341814B (zh) * 2017-01-23 2021-09-03 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
FI3595667T3 (fi) 2017-03-14 2024-01-12 Galapagos Nv Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
CN111479810B (zh) * 2018-01-31 2022-11-22 珠海联邦制药股份有限公司 Jak抑制剂及其应用
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
EP3758700B1 (en) 2018-02-28 2024-07-31 University of Southern California Compositions for modulating inflammatory and degenerative disorders
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
ES2973331T3 (es) * 2018-08-23 2024-06-19 Zhuhai United Laboratories Co Ltd Compuesto de [1,2,4]triazolo[1,5-a]piridina como inhibidor de JAK y aplicación del mismo
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP2022515256A (ja) 2018-12-25 2022-02-17 ソル － ゲル テクノロジーズ リミテッド Ｅｇｆｒ阻害剤を含む組成物による皮膚障害の治療
TW202116754A (zh) 2019-07-11 2021-05-01 美商Ｅ 斯蓋普生物股份有限公司 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑
CN111892592B (zh) * 2019-08-06 2023-09-19 江苏柯菲平医药股份有限公司 Jak激酶抑制剂及其用途
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
US12214216B1 (en) 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
AU2020428591B2 (en) * 2020-02-13 2024-05-23 Zhuhai United Laboratories Co., Ltd. Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
WO2021168375A1 (en) 2020-02-20 2021-08-26 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
WO2021164786A1 (zh) * 2020-02-21 2021-08-26 珠海联邦制药股份有限公司 Jak抑制剂的晶型及其应用
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN111617318B (zh) * 2020-05-26 2021-12-10 南京市儿童医院 可注射型儿童骺板再生水凝胶的制备方法
CN114075188A (zh) * 2020-08-11 2022-02-22 南京柯菲平盛辉制药有限公司 芳香杂环酰胺类化合物及其制备方法和医药用途
CN114075189A (zh) * 2020-08-11 2022-02-22 南京柯菲平盛辉制药有限公司 五元杂环并苯环类化合物及其制备方法和医药用途
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN114394965B (zh) * 2021-01-29 2023-09-12 深圳市乐土生物医药有限公司 三唑并吡啶类化合物及其制备方法与用途
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN116354955A (zh) * 2021-12-28 2023-06-30 上海科胜药物研发有限公司 一种菲戈替尼的制备方法
CN116496268A (zh) * 2022-01-18 2023-07-28 盛世泰科生物医药技术(苏州)有限公司 一种含环丙酰胺化合物及其应用
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
US11746108B1 (en) * 2022-06-13 2023-09-05 Apm Therapeutics 1, Inc. Triazolopyridine polymorph A
CN116687925B (zh) * 2022-11-04 2024-10-22 中国科学院遗传与发育生物学研究所 一种侵蚀性蛋白酶抑制剂及其应用
LU505465B1 (en) * 2022-11-16 2024-05-14 Adlai Nortye Biopharma Co Ltd A pan-KRAS inhibitor compound
KR20260054550A (ko) * 2024-10-15 2026-04-22 한국화학연구원 JAK1를 선택적으로 저해하는 신규한 테트라하이드로이소퀴놀린 또는 이소인돌린 치환 [1,2,4]트리아졸로[1,5-a]피리딘 유도체 및 이의 용도
CN119462650B (zh) * 2024-11-20 2025-10-17 沈阳药科大学 一种非戈替尼的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (en) * 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
TWI221602B (en) * 2003-07-21 2004-10-01 Benq Corp Emergent disc-withdrawing apparatus
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
ATE495743T1 (de) * 2006-12-01 2011-02-15 Galapagos Nv Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9088430B2 (en) * 2008-02-19 2015-07-21 Qualcomm Incorporated Providing network originated push messages for remotely testing a mobile device
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
DE102009000543A1 (de) * 2009-02-02 2010-08-12 Evonik Degussa Gmbh Verfahren, Absorptionsmedien und Vorrichtung zur Absorption von CO2 aus Gasmischungen
JP5679995B2 (ja) * 2009-02-02 2015-03-04 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 酸性ガスの除去のための環式アミン含有吸収剤
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MX368511B (es) 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.

Also Published As

Publication number Publication date
MA32551B1 (fr) 2011-08-01
RS52823B (sr) 2013-10-31
CA2730762C (en) 2017-11-21
CY1115569T1 (el) 2017-01-04
PL2346864T3 (pl) 2013-08-30
JP5559168B2 (ja) 2014-07-23
SMT201400072B (it) 2014-09-08
US10206907B2 (en) 2019-02-19
ZA201100396B (en) 2011-10-26
US20150150856A1 (en) 2015-06-04
CN102105472B (zh) 2013-04-17
AU2009273144B2 (en) 2013-10-31
HK1158634A1 (en) 2012-07-20
KR20110045020A (ko) 2011-05-03
PT2346864E (pt) 2013-04-04
IL210262A0 (en) 2011-03-31
US20100029709A1 (en) 2010-02-04
BRPI0916659B8 (pt) 2021-05-25
EA018080B1 (ru) 2013-05-30
CN102105471A (zh) 2011-06-22
US20110190260A1 (en) 2011-08-04
DK2361251T3 (da) 2014-07-21
AR072875A1 (es) 2010-09-29
AU2009273143A1 (en) 2010-01-28
KR101711911B1 (ko) 2017-03-03
EP2361251A1 (en) 2011-08-31
WO2010010190A1 (en) 2010-01-28
EA201170255A1 (ru) 2011-08-30
BRPI0916862B8 (pt) 2021-05-25
SMT201300051B (it) 2013-07-09
PT2361251E (pt) 2014-07-11
CO6361925A2 (es) 2012-01-20
BRPI0916659A2 (pt) 2019-03-12
EA201170257A1 (ru) 2011-08-30
BRPI0916862B1 (pt) 2020-08-11
BRPI0916862A2 (pt) 2016-02-10
CA2730762A1 (en) 2010-01-28
SI2361251T1 (sl) 2014-09-30
CN102105471B (zh) 2014-10-15
CR20110092A (es) 2011-03-16
PE20100152A1 (es) 2010-03-24
HRP20130357T1 (en) 2013-05-31
MX2011000756A (es) 2011-03-21
KR101676391B1 (ko) 2016-11-15
NZ590646A (en) 2011-11-25
IL210262A (en) 2014-09-30
ME02046B (me) 2015-05-20
MX2011000758A (es) 2011-02-23
AU2009273144A1 (en) 2010-01-28
US20170035738A1 (en) 2017-02-09
UY32006A (es) 2010-02-26
KR20110053435A (ko) 2011-05-23
MY157615A (en) 2016-06-30
EA018587B1 (ru) 2013-09-30
JP2011529032A (ja) 2011-12-01
RS53406B (sr) 2014-10-31
US8853240B2 (en) 2014-10-07
CN102105472A (zh) 2011-06-22
AU2009273143B2 (en) 2014-01-23
ES2485913T3 (es) 2014-08-14
BRPI0916659B1 (pt) 2020-12-08
CA2730757A1 (en) 2010-01-28
TWI447118B (zh) 2014-08-01
JP2011529033A (ja) 2011-12-01
HK1158635A1 (en) 2012-07-20
IL210261A0 (en) 2011-03-31
DK2346864T3 (da) 2013-05-13
EP2346864B1 (en) 2013-03-06
ES2406691T3 (es) 2013-06-07
TW201008939A (en) 2010-03-01
US9415037B2 (en) 2016-08-16
EP2346864A1 (en) 2011-07-27
US20120309784A1 (en) 2012-12-06
US8242274B2 (en) 2012-08-14
CY1113945T1 (el) 2016-07-27
IL210261A (en) 2017-03-30
SI2346864T1 (sl) 2013-05-31
JP5480261B2 (ja) 2014-04-23
PL2361251T3 (pl) 2014-10-31
HRP20140681T1 (hr) 2014-10-24
DOP2011000022A (es) 2011-03-31
WO2010010191A1 (en) 2010-01-28
JO3041B1 (ar) 2016-09-05
ZA201100472B (en) 2011-10-26
EP2361251B1 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
AR072875A1 (es) Compuesto de [1,2,4]triazol[1,5-a]piridina inhibidor de tirosinquinasas jak, util en el tratamiento de enfermedades degenerativas e inflamatorias.
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
CO6270364A2 (es) Derivados de piridina y pirazina utiles en el tratamiento de trastornos de proliferacion celular
CL2012001971A1 (es) Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras.
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
CL43596B (es) Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica.
PE20130230A1 (es) Derivados de carboxamidas n-azabiciclicas y su preparacion
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
AR075204A1 (es) Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CL2008000180A1 (es) Sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4-(pirrolidin-1-ilmetil)fenil]ciclobutanocarboxamida; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como depresion, trastornos del sueno, ansiedad y enfermedades del tracto
UY30759A1 (es) Compuestos quimicos
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
UY27781A1 (es) Compuestos químicos.
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
CL2007001481A1 (es) Compuestos derivados de pirrolidina sustituidas, inhibidores de proteasa activadora de canal; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como fibrosis quistica, bronquitis cronica, epoc, asma e infecciones de las vias r
AR068919A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)[1,2,4]triazol-1-il]-n-etil-acetamida y analogos del mismo, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos psicoticos y/o enfermedades con dificultades intelectuales.
UY31141A1 (es) Compuestos de piperidina y sus usos
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas